The Readout Loud

STAT
  • 5,0 (6)
  • WIRTSCHAFT
  • WÖCHENTLICH
The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

  1. VOR 5 TAGEN

    332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

    Atlas Venture Partner Bruce Booth joins the podcast to discuss his annual year in review report, the influence of China, and what the new Trump administration might mean for innovation. Adam and Allison also recap the latest news in the life sciences, including a new science chief at Pfizer, a new job for Ned Sharpless, and the ongoing presidential appointments.

    35 Min.

  2. 14. NOV.

    331: AbbVie’s stumble, Amgen’s tumble and more election fallout

    Why are AbbVie executives feeling the M&A blues? What does it take to slice $12 billion from Amgen’s market value? And why are STAT’s D.C. correspondents working so hard?  We talk about all that and more on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. It’s a “Chatty Cathy” episode! Elaine, Allison and Adam lead off with a discussion about AbbVie’s M&A miscue following the failure of a closely followed schizophrenia drug. You’d hate us if obesity drugs weren’t mentioned, so we oblige with a tick-tock on what went down between Amgen and a Wall Street analyst who noted a possible safety issue with the obesity drug candidate MariTide.

    30 Min.

  3. 7. NOV.

    330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

    To dig into how the election results could affect all things biopharma, we brought on three guests for this episode: Lizzy Lawrence, STAT’s FDA reporter, Baird analyst Brian Skorney, and longtime biotech executive Daphne Zohar.

    39 Min.

  4. 31. OKT.

    329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story

    Adam, Allison, and Elaine get into the Halloween spirit this week, discussing their favorite candies — and Eli Lilly and Pfizer's surprise earnings reports. Then, they discuss what a Trump or Harris presidency could mean for health care and the biopharma industry, and what investors and biopharma executives think about either outcome.

    28 Min.

  5. 24. OKT.

    328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

    Will an activist investor campaign against Pfizer lead to big changes at the struggling Pharma giant? Why are some experts questioning the regulatory standards used to approve gene therapies for Duchenne muscular dystrophy? What’s the difference between Novo Holdings and Novo Nordisk, and will it impact a $16 billion acquisition of Catalent? And what lies ahead for Robert F. Kennedy Jr. and the Make America Healthy Again movement?

    34 Min.

  6. 17. OKT.

    327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights

    Elaine, Allison, and Adam chat about investors' interest in using CAR-T to treat autoimmune conditions, the latest developments with the supply of Eli Lilly’s blockbuster weight loss drug, and the invisible medical groups behind the dozens of telehealth platforms providing GLP-1 drugs. They also look back at STAT's two-day summit that brought together biopharma executives, scientists, policymakers and patient advocates for conversations about the future of health care.

    34 Min.

  7. 10. OKT.

    326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI

    First, biotech veteran John Maraganore calls in to discuss his new startup, City Therapeutics, this week's Nobel Prize awards, and the nerdy accolade he just received. Then STAT's Megan Molteni tells us about "CRISPR baby" scientist He Jiankui and his new cryptocurrency financier.

    40 Min.

  8. 3. OKT.

    325: Biden's health care AI czar, a new obesity company, and its dealmaking CEO

    Our colleague Mohana Ravindranath joins us to talk about Micky Tripathi, charged with coordinating how AI is used across different government agencies and more broadly across the health care industry. We also chat about some important biotech study readouts due before the end of the year, a new, well-funded obesity company, and the successful serial CEO running it. Finally, Adam and Allison lament the fact that Elaine hasn't yet watched the first episode of this season's "Great British Baking Show."

    33 Min.
Alle anzeigen (336)

Moderation und Gäste

Bewertungen und Rezensionen

5
von 5
6 Bewertungen

Info

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Informationen

  • Erstellt von
    STAT
  • Jahre aktiv
    2018 - 2024
  • Folgen
    336
  • Bewertung
    Unbedenklich
  • Copyright
    © All rights reserved
  • Sendungswebsite
    The Readout Loud

Das gefällt dir vielleicht auch

Melde dich an, um anstößige Folgen anzuhören.

Bleib auf dem Laufenden mit dieser Sendung

Melde dich an oder registriere dich, um Sendungen zu folgen, Folgen zu sichern und die neusten Updates zu erhalten.
Wähle ein Land oder eine Region aus

Afrika, Naher Osten und Indien

Asien/Pazifik

Europa

Lateinamerika und Karibik

USA und Kanada